One of the key aspects of any strategy for gene therapy is the system used for gene delivery, and several of these were individually reviewed. Currently, virus-based (particularly retrovirus) delivery systems are most numerous. These in general use well-established technology based on Moloney murine leukaemia virus, and this system is the basis of the majority of the current attempts in therapeutic delivery. Although However, viruses are not the only means of transferring genes to target tissues, although they can be used as accessory agents in some other forms of delivery. One such instance is the receptor-mediated gene delivery system described by Matt Cotten (Vienna). This consists of the DNA to be transfected, condensed with a polycation (e.g. polylysine), inclusion of a cell receptor-recognising component (e.g. transferrin) and streptavidin. Chemically inactivated, biotinylated adenovirus particles are bound to the complex via the streptavidin-biotin interaction and provide an endosome disruption activity required for exit of the complex from endosomes. The transfection process appears to be efficient and, since the DNA is not subject to the size constraints imposed by a viral vector system, can be employed to transfer large segments of genetic information. In addition variation of the cell-binding agent offers the prospect of a degree of cell targeting.
One of the key aspects of any strategy for gene therapy is the system used for gene delivery, and several of these were individually reviewed. Currently, virus-based (particularly retrovirus) delivery systems are most numerous. These in general use well-established technology based on Moloney murine leukaemia virus, and this system is the basis of the majority of the current attempts in therapeutic delivery. Although apparently satisfactory in many situations, the current generation of vectors suffers from a number of disadvantages such as relatively poor infectivity for human cells and the possibility of reactivation of endogenous replicationcompetent retroviral genetic elements. Mary Collins (London) A second human trial aimed at correcting the cystic fibrosis (CF) defect was described by Alan Smith. In vitro experiments demonstrated that relatively low multiplicities of infection of CF cells in culture by a recombinant adenovirus would correct both the fluid transport and electro-physiological defects of the cells. A trial was devised whereby a small area of the nasal epithelium was infected with the recombinant. Expression of the gene and correction of electrophysical defects in the treated cells was demonstrated.
Recombinant adenovirus has also been used in a mouse model of muscular dystrophy. Perricaudet described a recombinant containing a 6.3 kb Becker-like dystrophin cDNA driven by the Rous sarcoma virus (RSV) promoter. A single intramuscular injection into 5-to 9-day-old dystrophindeficient mdx mice resulted in expression of the dystrophin gene within the muscle cells for at least 6 months. In addition, the treated muscles were protected against degeneration.
An alternative ex vivo approach for muscular dystrophy, that of genetically correcting and retransplanting myogenic stem cells, was discussed by Terry Partridge (London). The attraction of this approach is that progressive repopulation of dystrophic muscle by the transduced myoblasts might eventually lead to genetic correction of whole muscle groups, circumventing one of the current problems with in vivo gene therapy of muscular dystrophy, namely that the extent of genetic correction seen in a muscle is generally limited to a small area around the site of administration of the therapeutic agent. Using a dystrophic mouse model he presented some evidence for such a primitive muscle progenitor cell capable of in vivo reconstitution and phenotype correction, and this approach may prove of some benefit in treating the major skeletal muscle groups.
To facilitate long-lived correction of a genetic defect it will be advantageous to target stem cells. Chris Potten (Manchester) defined stem cells as self-renewing, proliferative cells with a large division potential capable of producing many progeny which may differentiate in a variety of ways. In vitro manipulation of stem (or at least very primitive progenitor) cell populations has proved possible for a number of systems, including haemopoietic, gut and muscle tissues. Ron McKay (NIH) described immortalised lines derived from nestin (a neural 'stem cell'-specific gene) positive cells which may be propagated in vitro, and when implanted into the developing hippocampus differentiate in vivo both morphologically and functionally and are synaptically integrated with the host brain. Cells such as this may prove useful targets for genetic therapy of brain disorders. However, there are difficulties in working with unimmortalised stem cells. These include their identification, targeting, small numbers, accessibility and slow cycle times (or even quiescence).
Wolfram Ostertag (Hamburg) discussed two areas which restrict the efficiency of retroviral-mediated gene transfer into haemopoietic stem cells. The first concerns the need to maintain the number and quality of progenitor cells in explanted material. Although cocktails of soluble growth factors may expand target cell populations, a net differentiative effect is often seen. Co-culture of target cells with stroma in the absence of added factors was found to be the best method of maintaining the quality of stem cells. The use of long-term bone marrow cultures provides just such conditions and may facilitate manipulation of haemopoietic stem cells (Leslie Fairbairn, Manchester) .
A further issue is development of retroviral vectors suitable both for high-titre infection of stem cells and maintenance of gene expression in their progeny. Ostertag demonstrated the value of forced retroviral passage in the selection of beneficial mutations, such as those which overcome the downregulation of long terminal repeat (LTR) function found in primitive cells. The application of this technique to recombinant retorviruses promises further increases in the efficiency and repertoire of retroviral vectors.
For many applications it is desirable to direct the expression of introduced genes to a specific subset of the recipient population. In this respect, studies of transcriptional control reported by Dan Tenen (Boston) and Frank Grosveld (Rotterdam) provided indications of the multiple levels at which transcriptional selectivity may be influenced. Tenen described the involvement of the PU.1 and SPI transcription factors in directing the macrophage-specific expression of the CD1lb and macrophage colony-stimulating factor (M-CSF) receptor genes. It is hoped that regulatory elements of this type will be invaluable in modulating the expression pattern of linked therapeutic genes. However, we still know very little about the establishment of gene transcription patterns during the developmental processes which will be-relevant to many gene therapeutic approaches. The presentation of Grosveld described multiple levels at which the transcription patterns of at least some endogenous genes are determined. Studies on the developmental regulation of the beta-globin gene locus have demonstrated a requirement for regulatory elements a large distance from their target genes. These 'locus control regions' (LCRs) consist of dispersed groups of transcription factor binding sites, and are absolutely required to establish highlevel, specific transcription in developing cells. The activity of regulatory regions located close to each gene of the betaglobin cluster is dependent upon interaction with LCR elements in a competitive manner. There is much still to learn about the involvement of long-range regulatory interactions and higher order chromatin structure in the establishment and maintenance of tissue-specific gene expression. Furthermore, it seems likely that the combination of elements required to achieve tissue-specific and prolonged expression of some genes may lead to a need to use larger therapeutic DNA sequences than can be accommodated in a retrovirus.
An obvious role for gene therapy is in the treatment of inherited genetic disorders, many of which are caused by single-gene defects. Indeed, the first therapeutic use of gene therapy was for the rare autosomal recessive disorder, severe combined immune deficiency (SCID), a consequence of defects in the gene encoding the enzyme adenosine deaminase (ADA) and which results in lymphopenia and deficits in both humoral and cellular immunity. Jay Ramsay (NIH) described these first treatments, which used retroviral gene transfer of a normal human ADA cDNA into peripheral T cells. The two patients in the trial have elevated ADA levels in peripheral blood lymphocytes which have been sustained for up to 12 months following infusion. Functionally, their immune systems show significant reconstitution with decreased frequencies and severities of infectious diseases and improved responses to immune challenges. These encouraging data have led to the development of strategies for haemopoietic stem cell gene therapy of this disease to achieve long-term improvement of immune function without the need for continued reinfusion.
Haemopoietic stem cell gene therapy is also the method of choice for other inherited disorders of the blood system. Mike Antoniou (London) addressed the problems associated with a gene therapy approach to the haemoglobinopathies (aand P-thalassemia, sickle cell anaemia). Although, given the complexities associated with controlled expression of globin genes, a gene therapeutic answer to these diseases may still be a long way off, the widespread nature of the haemoglobinopathies (compared with the relative rarity of, for example, ADA-SCID) makes a powerful case for substantial technological investment in their treatment.
The When there is no significant neurological involvement in a disorder, and thus no need for delivery of product across the blood-brain barrier, other tissues also lend themselves as targets for transfer of genes encoding secreted proteins. Oliver Danos (Paris) described such an approach for another lysosomal storage disorder, mucopolysaccharidosis (MPS) VII (Sly syndrome). Primary fibroblasts from MPS VII mice were transduced with a retrovirus expressing human 1B-glucuronidase, embedded in a collagen lattice and reimplanted. Danos and colleagues saw vascularisation of the neo-organ, accumulation of enzyme in some tissues and correction of the storage lesions in those tissues. Scaled-up experiments using a dog model of the disease suggest that this approach is feasible for larger animals. David Lane (Dundee) discussed the possibility of using one of the genetic defects of a tumour as a target for genetic therapy of disease. A common feature of many different tumours is loss of function of a specific gene product, and a number of these commonly lost genes are tumour suppressors, of which the retinoblastoma and the p53 genes are the best-known examples. Restoration of wild-type p53 function to tumour cells can lead to dramatic growth-inhibitory or lethal effects. A further feature of normal p53 is that it is markedly more stable in tumour cells than in normal cells. cription factor which binds to a response element within the c-erbB-2 promoter. Thus it may prove possible to achieve high levels of cytosine deaminase in some tumour cells compared with normal tissues. Since cytosine deaminase converts 5-fluorocytosine (5-FC) to the cytotoxic agent 5-fluorouracil, it follows that such cells would be selectively killed after administration of 5-FC to a patient.
In a similar approach, Zvi Ram and colleagues (NIH) have used retroviruses carrying the herpes simplex virus thymidine kinase (HStk) gene to express this gene in tumour cells. In animals models of brain tumours, they were able to obtain transfer and expression of HStk in the cycling neoplastic cell population after direct injection of retroviral producers into the tumours. The quiescent normal cells of the brain appeared largely unaffected, and following treatment with the prodrug pre-established tumours were seen to regress. Subsequently a clinical trial treating eight patients with unresponsive, progressive malignant brain tumours has been initiated. In five of the eight patients treated some evidence of an anti-tumour response (decrease in tumour size or changes in tumour consistency) was seen. Although this trial was not intended as a full therapeutic treatment but was designed to evaluate toxicity and the potential for anti-tumour activity in vivo in humans, the data thus far look extremely promising with anti-tumour effects being achieved without any treatment-associated toxicity being observed. Based on data from animal models, it is unlikely that all the tumour cells which were killed were transduced with the HStk retrovirus. This phenomenon, known as the bystander effect, in which induction of death in some cells leads to death of surrounding ones, is not well understood. However, it is likely that a number of effects, including transfer of activated drug via gap junctions or by intercellular diffusion, destruction of tumour microcirculation and activation of an immune response, may contribute to the cell death seen.
The meeting ended with a session devoted to regulatory, ethical and safety considerations. Sir Cecil Clothier (Chairman of the first government-appointed committee to examine the implications of gene therapy) pointed out that all attempts to restrain or confine the progress of science are contrary to man's nature and therefore will fail. However, there is always the temptation to abuse scientific developments, the motive usually being profit. The more blatant of such abuses drive society to legal regulation. Clothier asserts that generally new technology is available only to a small number of individuals who are of high integrity but that, as time goes by, technology advances and becomes more widely available, at which time the abusers move in. Therefore regulation can and should be voluntary at first, but once the scope for abuse is determined legal controls should be applied.
John Harris (Manchester) considered ethical issues, in particular the distinction between somatic and germ-line therapy. The general perception had been that these forms of therapy are fundamentally different from an ethical point of view and should be regulated differently. However Clothier clarified his committee's thesis that rather than being an ethical issue, the current distinction between the two was on the grounds of current lack of availability of knowledge of the consequences of gene therapy and that as more became known we would be better able to contemplate germ-line therapy.
Tony Meager (Potter's Bar) concluded the presentations with a sobering enumeration of the extensive requirements of safety regulatory authorities' demands for vector and product characterisation, stringent testing for a large number of undesirable agents, criteria for containment and operating standards of production facilities and the need for comprehensive documentation of reagents and procedures.
